Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma

October 1, 2014 Immunovaccine Inc. (“Immunovaccine” or “IMV”), a clinical stage vaccine and immunotherapy company, today provided a clinical development program update for DPX-Survivac, the Company’s lead cancer vaccine candidate. Following the presentation of positive Phase I/II clinical trial data at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting earlier this year, the Company plans to advance DPX-Survivac …